Trial in progress: A phase 1B/2 study of GB5121, a novel, highly selective, potent, and CNS-penetrant inhibitor of Bruton’s tyrosine kinase (BTKI) for relapsed/refractory primary/secondary CNS lymphoma (R/R PCNSL/SCNSL) and primary vitreoretinal lymphoma (PVRL) Meeting Abstract
| Authors: | Soussain, C.; Grommes, C.; Issa, S.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B.; Ding, Z.; Yusuf, I.; Rose, M.; Steinberg, M.; Tun, H. W. |
| Abstract Title: | Trial in progress: A phase 1B/2 study of GB5121, a novel, highly selective, potent, and CNS-penetrant inhibitor of Bruton’s tyrosine kinase (BTKI) for relapsed/refractory primary/secondary CNS lymphoma (R/R PCNSL/SCNSL) and primary vitreoretinal lymphoma (PVRL) |
| Meeting Title: | 2nd Annual Conference on CNS Clinical Trials and Brain Metastases |
| Journal Title: | Neuro-Oncology Advances |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Aug 11-12 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 2632-2498 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-08-01 |
| Start Page: | i9 |
| Language: | English |
| DOI: | 10.1093/noajnl/vdac078.035 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: CLRM-15 -- Co-Sponsored by SNO and ASCO |
